Suven Life Sciences, a biopharmaceutical company, announced today the grant of five product patents for New Chemical Entities (NCEs) in five countries.

The company has secured one product patent from Australia (2010340745), one product patent from Europe (2121602), one product patent from Hong Kong (1159626), one product patent from Israel (211747) and one product patent from Norway (335838) for the treatment of disorders associated with Neurodegenerative diseases.

''We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,'' says Venkat Jasti, CEO of Suven.

Shares of the company gained Rs 8.3, or 2.76%, to trade at Rs 308.50. The total volume of shares traded was 290,404 at the BSE (10.20 a.m., Friday).